Dermorphin
$Potent opioid peptide; Not a wellness peptide
Dermorphin is a mu-opioid receptor agonist peptide. It belongs in the guide because it is a peptide, but it should not be grouped with repair, cosmetic, or metabolic peptides.
Here, the safety context outweighs the potential-use discussion. Opioid-receptor potency creates risk for respiratory depression, dependence, withdrawal, contamination, and anti-doping violations. Read this as a red-flag compound, not a recovery tool.
“Peptide” is a chemical descriptor, not a safety descriptor: a peptide can still be an opioid, hormone, growth factor, or drug of abuse.
Classification details
- Dermorphin is a natural heptapeptide first isolated from South American tree frogs.
- It contains D-alanine in its natural sequence and is a potent opioid peptide.
- Dermorphin is a potent opioid peptide that sits in a high-risk category, not a performance, recovery, or wellness category. Its history includes illicit performance manipulation concerns, which changes how you should interpret it.
- Dermorphin acts primarily through mu-opioid receptor signaling.
- Analgesic potency, endocrine changes, and CNS effects are opioid effects and carry the usual opioid risks.
- The mechanism is mu-opioid receptor agonism. Analgesia or euphoria from opioid activity is not tissue repair and can mask injury or toxicity.